<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239408</url>
  </required_header>
  <id_info>
    <org_study_id>205.282</org_study_id>
    <nct_id>NCT00239408</nct_id>
  </id_info>
  <brief_title>Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).</brief_title>
  <official_title>Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-month Parallel Group, Double-blind, Randomised, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced
      expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary
      disease (COPD), is affected by smoking status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate whether the effect of inhaled tiotropium bromide on the change in trough FEV1 from
      baseline to week 12 compared to placebo in patients with COPD is affected by smoking status.
      Secondary objectives include FEV1 at interim visit and FVC at on-treatment visits, use of
      rescue medication, COPD symptom scores, Physicians Global Evaluation and EQ-5D scores.

      Study Hypothesis:

      The primary objective of the study is to show superiority of tiotropium against placebo with
      respect to trough FEV1 at 12 weeks. Then the 5% two-sided hypotheses test is:

      H0: Mean trough FEV1 at 12 weeks in tiotropium = Mean trough FEV1 at 12 weeks in placebo H1:
      Mean trough FEV1 at 12 weeks in tiotropium unequal Mean trough FEV1 at 12 weeks in placebo If
      the null hypothesis is rejected in favour of the alternative hypothesis (H1) based on all
      patients, the same hypotheses will be tested in both sub-populations of current and
      ex-smokers respectively.

      Comparison(s):

      Tiotropium bromide - 18 mcg capsule inhaled via the HandiHaler vs Placebo powder capsules for
      oral inhalation, via the HandiHaler.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date>April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in trough FEV1 after 12 weeks of treatment.</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 at interim visit</measure>
    <time_frame>week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC at weeks 6 and 12</measure>
    <time_frame>week 6, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication (daytime and night-time)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of COPD symptoms</measure>
    <time_frame>week 0, week 6, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Physician's Global Evaluation at Visits 2 and 4</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (EQ-5D) at Visits 2 and 4</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment>311</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulmonary function Testing</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion criteria: 1.Diagnosis of chronic obstructive pulmonary disease. 2.Patient is
        male or female, age &lt;=than 40 years. 3. Patient has a smoking history of &lt;=10
        pack-year.4.Patient is able to be trained in the proper use of HandiHaler 5.Patient is able
        to be trained to perform technically satisfactory spirometry and must be able to maintain
        records during the study period as required by the protocol. 6.Patient must be willing and
        able to sign informed consent prior to participation in the study i.e. prior to washout of
        their usual pulmonary medications.

        Main exclusion criteria 1.History of asthma, allergic rhinitis or atopy. 2. A lower
        respiratory tract infection or any COPD exacerbation in the past 4 weeks prior to Visit 1
        or during the two week Screening Period 3.History of life threatening bronchial
        obstruction, cystic fibrosis or bronchiectasis 4. Oral corticosteroid medication if
        initiated or modified within the last 6 weeks prior to Visit 1 or if daily dose &gt; 10 mg
        prednisone or 20 mg or more every other day (or equivalent). 5.Patients who have started or
        stopped an exercise rehabilitation program within 4 weeks of visit 6.Patients who regularly
        use daytime oxygen therapy for more than one hour per day and who, in the investigator's
        opinion, will be unable to abstain from the use of oxygen therapy during testing. 7.
        Patients who have undergone thoracotomy with pulmonary resection or lobectomy (lung volume
        reduction surgery). 8.Tuberculosis with indication for treatment. 9. Recent history (i.e. 6
        months or less) of myocardial infarction.10. Patients with known moderate or severe renal
        insufficiency.11. Patients with symptomatic prostatic hypertrophy or bladder neck
        obstruction. 12.Patients with known narrow-angle glaucoma.13.History of unstable arrhythmia
        with a life threatening event or change of therapy during the past year.14. History of
        cancer, other than treated basal cell carcinoma, within the last 5 years 15.Intolerance to
        anticholinergic containing products, and/or to lactose or any other components of the
        inhalation capsule delivery system.16.Patients who are being treated with beta-blockers
        including eye drops.17.Patients who are being treated with antihistamines (H1 receptor
        antagonists), for asthma or excluded allergic conditions (See Exclusion Criteria
        No.2).18.Patients who are being treated with monoamine oxidase inhibitors or tricyclic
        antidepressants.19. Patients who are being treated with oral beta-adrenergics.20. Patients
        who have taken cromolyn sodium or nedocromil sodium within 1 month of Visit 1.21.Patients
        who have taken antileukotrienes or leukotriene receptor antagonists within 1 month of Visit
        1. 22.Concomitant or recent (within the last month or 6 half lives, whichever is greater)
        use of investigational drugs prior to the screening visit (Visit 1). 23. Significant
        alcohol or drug abuse within the past 12 months. 24. Pregnant or nursing women or women of
        childbearing potential not using a medically approved means of contraception.24. Previous
        participation in this study (i.e. randomized).26. Patients who have taken commercially
        available Spiriva. 27.History of any clinically significant disease, defined as a disease
        which in the opinion of the investigator may the patient at risk because of participation
        in the study OR a disease which may influence the results of the study OR the patient's
        ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Portugal Lda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <zip>2800-525 Almada</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando Fonseca</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276Amadora</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santo Espírito de Angra do Heroismo</name>
      <address>
        <city>Angra do Heroismo - Açores</city>
        <zip>9700-856</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infante D. Pedro</name>
      <address>
        <city>Aveiro</city>
        <zip>3810</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidade Funcional de Infecciologia</name>
      <address>
        <city>Barreiro</city>
        <zip>2830-094</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Marcos</name>
      <address>
        <city>Braga</city>
        <zip>4701-965</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3040-853</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar da Cova da Beira</name>
      <address>
        <city>Covilhã</city>
        <zip>6200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital de Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital da Figueira da Foz</name>
      <address>
        <city>Figueira da Foz</city>
        <zip>3080-707</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Funchal</name>
      <address>
        <city>Funchal</city>
        <zip>9004-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sousa Martins</name>
      <address>
        <city>Guarda</city>
        <zip>6300-749</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Senhora da Oliveira</name>
      <address>
        <city>Guimarães</city>
        <zip>4810-055</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Particular de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-142</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia Francisco Gentil</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Marta - HCL</name>
      <address>
        <city>Lisboa</city>
        <zip>1196-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulido Valente</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Egas Moniz</name>
      <address>
        <city>Lisbon</city>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saúde de Matosinhos</name>
      <address>
        <city>Matosinhos</city>
        <zip>4454-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Divino Espírito Santo</name>
      <address>
        <city>Ponta Delgada - Açores</city>
        <zip>9500-370</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Barlavento Algarvio</name>
      <address>
        <city>Portimão</city>
        <zip>8500-338</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4050-011</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de São João</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joaquim Urbano</name>
      <address>
        <city>Porto</city>
        <zip>4300</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital de Santarém</name>
      <address>
        <city>Santarém</city>
        <zip>2000-153</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Bernardo</name>
      <address>
        <city>Setúbal</city>
        <zip>2910</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Sebastião</name>
      <address>
        <city>Sta. Maria da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rainha Santa Isabel</name>
      <address>
        <city>Torres Novas</city>
        <zip>2354-909</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de V. N. de Gaia</name>
      <address>
        <city>V.N.Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Teotónio</name>
      <address>
        <city>Viseu</city>
        <zip>3504-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Espírito Santo</name>
      <address>
        <city>Évora</city>
        <zip>7000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

